Retrospective analysis of the perioperative volume management regarding the overall outcome in patients undergoing radical cystectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020541

Enrollment

250

Registered

2020-04-28

Start date

2019-09-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: All patients after radical Cystectomie - Evaluation of the perioperative volume therapy and transfusion therapy in radical cystectomies regarding advantages and disadvantages on the postopera

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Radical Cystectomie between 01.03.2009 and 31.12.2018 at University Hospital Freiburg

Exclusion criteria

Exclusion criteria: Unter 18 Years

Design outcomes

Primary

Measure	Time frame
Perioperative total amount of volume therapy [ml] intraoperative / first 24h Perioperative gastrointestinal complications [yes/no] / 90 days after surgery	—

Secondary

Measure	Time frame
(coronary heart disease (CHD) arterial hypertension (aHT) Lung disease Liver diseases ASA status Nicotine abuse Alcohol abuse diabetes mellitus Tumor stage Hydronephrosis perioperative chemotherapy anemia) preoperative, [yes/no] (maximum catecholamine dose [µg/kg/min]: Inotropics [yes/no] Total amount of crystalloids Volume solution [ml] Total amount of colloidal volume solution [ml]. Total amount of blood products [ml] OP duration [min] peridural catheter [running rate, medication]) intraoperative Import/export/ balance of the first 24h post-operation [ml] - Catecholamines during the first 24h post-op [yes/no]. - max. running rate of catecholamines during the first 24h [ug/kg/min] Type of urinary diversion [Type] -pelvine lymphadenectomy [yes/no] Days to oral food intake [days]. Days until first bowel movement / flatulence [days]. Wound healing disorder [yes/no, type] 90 days after surgery Pulmonary complications [yes/no, type] 90 days after surgery cardiac complications [yes/no, type] 90 days after surgery Mortality Hospitalization period [days] after surgery eGFR/crea pre-OP [ml/min, mg/dl] -eGFR- / 24h/ 7days [ml/min, mg/dl] -eGFR- / 24h/ 7days [ml/min, mg/dl Diuresis over 24h post-op [ml] Body height [cm] Body weight (BMI) [kg].	—

Measure

Time frame

(coronary heart disease (CHD) arterial hypertension (aHT) Lung disease Liver diseases ASA status Nicotine abuse Alcohol abuse diabetes mellitus Tumor stage Hydronephrosis perioperative chemotherapy anemia) preoperative, [yes/no] (maximum catecholamine dose [µg/kg/min]: Inotropics [yes/no] Total amount of crystalloids Volume solution [ml] Total amount of colloidal volume solution [ml]. Total amount of blood products [ml] OP duration [min] peridural catheter [running rate, medication]) intraoperative Import/export/ balance of the first 24h post-operation [ml] - Catecholamines during the first 24h post-op [yes/no]. - max. running rate of catecholamines during the first 24h [ug/kg/min] Type of urinary diversion [Type] -pelvine lymphadenectomy [yes/no] Days to oral food intake [days]. Days until first bowel movement / flatulence [days]. Wound healing disorder [yes/no, type] 90 days after surgery Pulmonary complications [yes/no, type] 90 days after surgery cardiac complications [yes/no, type] 90 days after surgery Mortality Hospitalization period [days] after surgery eGFR/crea pre-OP [ml/min, mg/dl] -eGFR- / 24h/ 7days [ml/min, mg/dl] -eGFR- / 24h/ 7days [ml/min, mg/dl Diuresis over 24h post-op [ml] Body height [cm] Body weight (BMI) [kg].

—

Countries

Germany

Contacts

Public ContactJulian Knörlein

Universitätsklinikum Freiburg

julian.knoerlein@uniklinik-freiburg.de004917654373198

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026